To investigate bat coronaviruses (CoVs), we collected 132 rectal swabs and urine samples from five bat species in three countries in southwestern China. Seven CoVs belonging to distinct groups of severe acute respiratory syndrome (SARS)-like CoVs and α-CoVs were detected in samples from least horseshoe bats. Samples from other bat species were negative for these viruses, indicating that the least horseshoe bat represents one of the natural reservoirs and mixers for strains of CoVs and has a pivotal role in the evolution and dissemination of these viruses. The genetic and evolutionary characteristics of these strains were described. Whole-genome sequencing of a new isolate (F46) from a rectal swab from a least horseshoe bat showed that it contained 29 699 nucleotides, excluding the poly (A) tail, with 13 open reading frames (ORFs). Phylogenetic and recombination analyses of F46 provided evidence of natural recombination between bat SARS-like CoVs (Rs3367 and LYRa11) or SARS-CoV (BJ01), suggesting that F46 could be a new recombinant virus from SARS-like CoVs or SARS-CoVs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378919 | PMC |
| http://dx.doi.org/10.1038/emi.2016.140 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Distinct pathways for evolution of enhanced receptor binding and cell entry in SARS-like bat coronaviruses.
PLoS Pathog
November 2024
Department of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, New York, New York, United States of America.
Article Synopsis
- Understanding bat coronaviruses (CoVs) is vital for preventing future pandemics, so researchers created modified viruses to study how these bat CoVs enter cells.
- They discovered a surprising change in a specific region of the virus that improved its ability to bind to a human receptor, enhancing its entry into cells.
- The study reveals how bat CoVs might adapt to jump between species and suggests strategies to target vulnerabilities in these viruses for potential prevention measures.
Structural determinants of spike infectivity in bat SARS-like coronaviruses RsSHC014 and WIV1.
J Virol
August 2024
The Ministry of Education Key Laboratory of Protein Science, Beijing, China.
Unlabelled: The recurrent spillovers of coronaviruses (CoVs) have posed severe threats to public health and the global economy. Bat severe acute respiratory syndrome (SARS)-like CoVs RsSHC014 and WIV1, currently circulating in bat populations, are poised for human emergence. The trimeric spike (S) glycoprotein, responsible for receptor recognition and membrane fusion, plays a critical role in cross-species transmission and infection.
View Article and Find Full Text PDFUnderstanding the zoonotic risks posed by bat coronaviruses (CoVs) is critical for pandemic preparedness. Herein, we generated recombinant vesicular stomatitis viruses (rVSVs) bearing spikes from divergent bat CoVs to investigate their cell entry mechanisms. Unexpectedly, the successful recovery of rVSVs bearing the spike from SHC014, a SARS-like bat CoV, was associated with the acquisition of a novel substitution in the S2 fusion peptide-proximal region (FPPR).
View Article and Find Full Text PDFDetection of Coronaviruses in Bats in Lebanon during 2020.
Pathogens
June 2023
Human Link DMCC, Dubai 115738, United Arab Emirates.
Bats are considered the main reservoir of coronaviruses (CoVs), and research evidence suggests the essential role of bats in the emergence of Severe Acute Respiratory Syndrome Coronaviruses (SARS-CoV) and SARS-CoV-2. SARS-CoV-like viruses have been recently detected in bats in different countries. In 2020, we conducted surveillance for CoVs among six different bat species in Lebanon.
View Article and Find Full Text PDFSafety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults.
Infect Dis Ther
May 2023
Invivyd, Inc., 1601 Trapelo Road, Suite 178, Waltham, MA, 02451, USA.
Introduction: Adintrevimab is a fully human immunoglobulin G1 extended half-life monoclonal antibody that was developed to have broad neutralization against SARS-CoV, SARS-CoV-2, and other SARS-like CoVs with pandemic potential. Here we report the safety, pharmacokinetics (PK), serum viral neutralizing antibody (sVNA) titers, and immunogenicity results of the first three cohorts evaluated in the first-in-human study of adintrevimab in healthy adults.
Methods: This is a phase 1, randomized, placebo-controlled, single ascending-dose study of adintrevimab administered intramuscularly (IM) or intravenously (IV) to healthy adults aged ≥ 18-55 years with no current or prior SARS-CoV-2 infection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!